Ni Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ni Su has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Fan Yang
Department of Bioengineering, Stanford University, Stanford, California, USA
3 shared publications Cassandra Villicana
Department of Bioengineering Stanford University School of Medicine Stanford CA 94305 USA
2 shared publications- Ying Luo
Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155, United States
2 shared publications Andrew Yang
Department of Bioengineering Stanford University School of Medicine Stanford CA 94305 USA
1 shared publicationBrice Gaudillière
Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, CA, USA
1 shared publication- Cassandra Villicana
Department of Bioengineering Stanford University School of Medicine Stanford CA 94305 USA
1 shared publication
Latest Publications
- 31 January 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (6) , e2402138
Incorporating Bone‐Derived ECM into Macroporous Microribbon Scaffolds Accelerates Bone Regeneration
Tissue‐derived extracellular matrix (tdECM) hydrogels serve as effective scaffolds for tissue regeneration by promoting a regenerative immune response. While most tdECM hydrogels are nanoporous and tailored for soft tissue, macroporosity is crucial for bone regeneration. Yet, there's a shortage of macroporous ECM‐based hydrogels for this purpose. The study aims to address this gap by developing a co‐spinning technique to integrate bone‐derived ECM (bECM) into gelatin‐based, macroporous microribbon (µRB) scaffolds. The effect of varying doses of bECM on scaffold properties was characterized. In vitro studies revealed 15% bECM as optimal for promoting MSC osteogenesis and macrophage (Mφ) polarization. When implanted in a mouse critical‐sized cranial bone defect model, 15% bECM with tricalcium phosphate (TCP) microparticles significantly accelerated bone regeneration and vascularization, filling over 55% of the void by week 2. Increasing bECM to 25% enhanced mesenchymal stem cell (MSC) recruitment and decreased M1 Mφ polarization but reduced overall bone formation and vascularization. The findings demonstrate co‐spun gelatin/bECM hydrogels as promising macroporous scaffolds for robust endogenous bone regeneration, without the need for exogenous cells or growth factors. While this study focused on bone regeneration, this platform holds the potential for incorporating various tdECM into macroporous scaffolds for diverse tissue regeneration applications.
- 31 January 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (6) , e2402138
Incorporating Bone‐Derived ECM into Macroporous Microribbon Scaffolds Accelerates Bone Regeneration
Tissue‐derived extracellular matrix (tdECM) hydrogels serve as effective scaffolds for tissue regeneration by promoting a regenerative immune response. While most tdECM hydrogels are nanoporous and tailored for soft tissue, macroporosity is crucial for bone regeneration. Yet, there's a shortage of macroporous ECM‐based hydrogels for this purpose. The study aims to address this gap by developing a co‐spinning technique to integrate bone‐derived ECM (bECM) into gelatin‐based, macroporous microribbon (µRB) scaffolds. The effect of varying doses of bECM on scaffold properties was characterized. In vitro studies revealed 15% bECM as optimal for promoting MSC osteogenesis and macrophage (Mφ) polarization. When implanted in a mouse critical‐sized cranial bone defect model, 15% bECM with tricalcium phosphate (TCP) microparticles significantly accelerated bone regeneration and vascularization, filling over 55% of the void by week 2. Increasing bECM to 25% enhanced mesenchymal stem cell (MSC) recruitment and decreased M1 Mφ polarization but reduced overall bone formation and vascularization. The findings demonstrate co‐spun gelatin/bECM hydrogels as promising macroporous scaffolds for robust endogenous bone regeneration, without the need for exogenous cells or growth factors. While this study focused on bone regeneration, this platform holds the potential for incorporating various tdECM into macroporous scaffolds for diverse tissue regeneration applications.
- 30 April 2024
- Published by Elsevier in Journal of Environmental Chemical Engineering
- Vol. 12 (3) , 112939
Construction of unique floating Bi2WO6/g-C3N4 S-scheme heterojunction to promote photocatalytic activity
- 30 April 2024
- Published by Elsevier in Journal of Environmental Chemical Engineering
- Vol. 12 (3) , 112939
Construction of unique floating Bi2WO6/g-C3N4 S-scheme heterojunction to promote photocatalytic activity
- 11 January 2023
- Published by Wiley in Advanced Materials
- Vol. 35 (10) , e2208781
Stem Cell Membrane‐Coated Microribbon Scaffolds Induce Regenerative Innate and Adaptive Immune Responses in a Critical‐Size Cranial Bone Defect Model
Naturally‐derived cell membranes have shown great promise in functionalizing nanoparticles to enhance biointerfacing functions for drug delivery applications. However, its potential for functionalizing macroporous scaffolds to enhance tissue regeneration in vivo remains unexplored. Engineering scaffolds with immunomodulatory functions represents an exciting strategy for tissue regeneration but is largely limited to soft tissues. Critical‐sized bone defects cannot heal on their own, and the role of adaptive immune cells in scaffold‐mediated healing of cranial bone defects remains largely unknown. Here, mensenchymal stem cell membrane (MSCM)‐coated microribbon (µRB) scaffolds for treating critical size cranial bone defects via targeting immunomodulation are reported. Confocal imaging and proteomic analyses are used to confirm successful coating and characterize the compositions of cell membrane coating. It is demonstrated that MSCM coating promotes macrophage (Mφ) polarization toward regenerative phenotype, induces CD8+ T cell apoptosis, and enhances regulatory T cell differentiation in vitro and in vivo. When combined with a low dosage of BMP‐2, MSCM coating further accelerates bone regeneration and suppresses inflammation. These results establish cell membrane‐coated microribbon scaffolds as a promising strategy for treating critical size bone defects via immunomodulation. The platform may be broadly used with different cell membranes and scaffolds to enhance regeneration of multiple tissue types.
- 11 January 2023
- Published by Wiley in Advanced Materials
- Vol. 35 (10) , e2208781
Stem Cell Membrane‐Coated Microribbon Scaffolds Induce Regenerative Innate and Adaptive Immune Responses in a Critical‐Size Cranial Bone Defect Model
Naturally‐derived cell membranes have shown great promise in functionalizing nanoparticles to enhance biointerfacing functions for drug delivery applications. However, its potential for functionalizing macroporous scaffolds to enhance tissue regeneration in vivo remains unexplored. Engineering scaffolds with immunomodulatory functions represents an exciting strategy for tissue regeneration but is largely limited to soft tissues. Critical‐sized bone defects cannot heal on their own, and the role of adaptive immune cells in scaffold‐mediated healing of cranial bone defects remains largely unknown. Here, mensenchymal stem cell membrane (MSCM)‐coated microribbon (µRB) scaffolds for treating critical size cranial bone defects via targeting immunomodulation are reported. Confocal imaging and proteomic analyses are used to confirm successful coating and characterize the compositions of cell membrane coating. It is demonstrated that MSCM coating promotes macrophage (Mφ) polarization toward regenerative phenotype, induces CD8+ T cell apoptosis, and enhances regulatory T cell differentiation in vitro and in vivo. When combined with a low dosage of BMP‐2, MSCM coating further accelerates bone regeneration and suppresses inflammation. These results establish cell membrane‐coated microribbon scaffolds as a promising strategy for treating critical size bone defects via immunomodulation. The platform may be broadly used with different cell membranes and scaffolds to enhance regeneration of multiple tissue types.
- Open Access
- 4 August 2022
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 36, 64-74
Differential dynamics of bone graft transplantation and mesenchymal stem cell therapy during bone defect healing in a murine critical size defect
- 4 August 2022
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 36, 64-74
Open AccessDifferential dynamics of bone graft transplantation and mesenchymal stem cell therapy during bone defect healing in a murine critical size defect
- Top Cited Papers
- 25 May 2022
- Published by Elsevier in Biomaterials
- Vol. 286, 121604
Immunomodulatory strategies for bone regeneration: A review from the perspective of disease types
- 25 May 2022
- Published by Elsevier in Biomaterials
- Vol. 286, 121604
Top Cited PapersImmunomodulatory strategies for bone regeneration: A review from the perspective of disease types
- 30 March 2022
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 14 (14) , 15942-15955
Immunomodulation of Telmisartan-Loaded PCL/PVP Scaffolds on Macrophages Promotes Endogenous Bone Regeneration
Biomaterial–immune system interactions play an important role in postimplantation osseointegration to retain the functionality of healthy and intact bones. Therefore, appropriate osteoimmunomodulation of implants has been considered and validated as an efficient strategy to alleviate inflammation and enhance new bone formation. Here, we fabricated a nanostructured PCL/PVP (polycaprolactone/polyvinylpyrrolidone) electrospinning scaffold for cell adhesion, tissue ingrowth, and bone defect padding. In addition, telmisartan, an angiotensin 2 receptor blocker with distinct immune bioactivity, was doped into PCL-/PVP-electrospun scaffolds at different proportions [1% (TPP-1), 5% (TPP-5), and 10% (TPP-10)] to investigate its immunomodulatory effects and osteoinductivity/conductivity. Telmisartan-loaded scaffolds displayed in vitro anti-inflammatory bioactivity on lipopolysaccharide-induced M1 macrophages by polarizing them to an M2-like phenotype and exhibited pro-osteogenic properties on bone marrow-derived mesenchymal stem cells (BMSCs). Histological analysis and micro-CT results of a rat skull defect model also showed that the telmisartan-loaded scaffolds induced a higher M2/M1 ratio, less inflammatory infiltration, and better bone regenerative patterns. Furthermore, activation of the BMP2 (bone morphogenetic protein-2)-Smad signaling pathway was found to be dominant in telmisartan-loaded scaffold-mediated macrophage–BMSC interactions. These findings indicate that telmisartan incorporation with PCL/PVP nanofibrous scaffolds is a potential therapeutic strategy for promoting bone healing by modulating M1 macrophages to a more M2 phenotype at early stages of postimplantation.
- 30 March 2022
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 14 (14) , 15942-15955
Immunomodulation of Telmisartan-Loaded PCL/PVP Scaffolds on Macrophages Promotes Endogenous Bone Regeneration
Biomaterial–immune system interactions play an important role in postimplantation osseointegration to retain the functionality of healthy and intact bones. Therefore, appropriate osteoimmunomodulation of implants has been considered and validated as an efficient strategy to alleviate inflammation and enhance new bone formation. Here, we fabricated a nanostructured PCL/PVP (polycaprolactone/polyvinylpyrrolidone) electrospinning scaffold for cell adhesion, tissue ingrowth, and bone defect padding. In addition, telmisartan, an angiotensin 2 receptor blocker with distinct immune bioactivity, was doped into PCL-/PVP-electrospun scaffolds at different proportions [1% (TPP-1), 5% (TPP-5), and 10% (TPP-10)] to investigate its immunomodulatory effects and osteoinductivity/conductivity. Telmisartan-loaded scaffolds displayed in vitro anti-inflammatory bioactivity on lipopolysaccharide-induced M1 macrophages by polarizing them to an M2-like phenotype and exhibited pro-osteogenic properties on bone marrow-derived mesenchymal stem cells (BMSCs). Histological analysis and micro-CT results of a rat skull defect model also showed that the telmisartan-loaded scaffolds induced a higher M2/M1 ratio, less inflammatory infiltration, and better bone regenerative patterns. Furthermore, activation of the BMP2 (bone morphogenetic protein-2)-Smad signaling pathway was found to be dominant in telmisartan-loaded scaffold-mediated macrophage–BMSC interactions. These findings indicate that telmisartan incorporation with PCL/PVP nanofibrous scaffolds is a potential therapeutic strategy for promoting bone healing by modulating M1 macrophages to a more M2 phenotype at early stages of postimplantation.
- Open Access
- 14 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (20) , eabf7207
Mesenchymal stromal exosome–functionalized scaffolds induce innate and adaptive immunomodulatory responses toward tissue repair
New exosome-laden scaffolds shed light on the immune cell activities that benefit tissue repair.
- 14 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (20) , eabf7207
Open AccessMesenchymal stromal exosome–functionalized scaffolds induce innate and adaptive immunomodulatory responses toward tissue repair
New exosome-laden scaffolds shed light on the immune cell activities that benefit tissue repair.
- 7 January 2019
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 20 (2) , 1007-1017
Membrane-Binding Adhesive Particulates Enhance the Viability and Paracrine Function of Mesenchymal Cells for Cell-Based Therapy
Understanding the fundamental cell-material interactions is essential to designing functional materials for biomedical applications. Although mesenchymal stromal cells (MSCs) are known to secrete cytokines and exosomes that are effective to treat degenerative diseases, the inherent property of biomaterials to modulate the therapeutic function of MSCs remains to be investigated. Here, a multivalent cell-membrane adhesive conjugate was generated through polyamindoamine (PAMAM) and an oligopeptide, IKVAV and the conjugate was further complexed with hyaluronic acids (HA). The adhesive particulates were used to coat the surface of adipose-derived mesenchymal stromal cells (Ad-MSCs) and studied in the MSC spheroid culture. The analysis showed that the adhesive complexes formed via PAMAM conjugates and HA significantly promoted the proliferation and the gene expression of pro-angiogenesis cytokines in MSCs; the production of anti-inflammatory miRNAs in exosomes could also be elevated. The transplantation of the Ad-MSCs primed with PAMAM-IKVAV/HA composite particulates in a rat myocardial infarction model further demonstrated the beneficial effects of membrane-binding materials on improving the cell retention and tissue angiogenesis. The new function of membrane-binding adhesive materials potentially provides useful ways to improve cell-based therapy.
- 7 January 2019
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 20 (2) , 1007-1017
Membrane-Binding Adhesive Particulates Enhance the Viability and Paracrine Function of Mesenchymal Cells for Cell-Based Therapy
Understanding the fundamental cell-material interactions is essential to designing functional materials for biomedical applications. Although mesenchymal stromal cells (MSCs) are known to secrete cytokines and exosomes that are effective to treat degenerative diseases, the inherent property of biomaterials to modulate the therapeutic function of MSCs remains to be investigated. Here, a multivalent cell-membrane adhesive conjugate was generated through polyamindoamine (PAMAM) and an oligopeptide, IKVAV and the conjugate was further complexed with hyaluronic acids (HA). The adhesive particulates were used to coat the surface of adipose-derived mesenchymal stromal cells (Ad-MSCs) and studied in the MSC spheroid culture. The analysis showed that the adhesive complexes formed via PAMAM conjugates and HA significantly promoted the proliferation and the gene expression of pro-angiogenesis cytokines in MSCs; the production of anti-inflammatory miRNAs in exosomes could also be elevated. The transplantation of the Ad-MSCs primed with PAMAM-IKVAV/HA composite particulates in a rat myocardial infarction model further demonstrated the beneficial effects of membrane-binding materials on improving the cell retention and tissue angiogenesis. The new function of membrane-binding adhesive materials potentially provides useful ways to improve cell-based therapy.